drugset
drugset / Trial / NCT03447145

A New Drug Used for Advanced Cancer

NCT03447145 ↗

Phase 1 Unknown 50 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To identify the safety and tolerance of TQ-B3203.

Timeline

Start
2017-12-26
Primary completion
2018-12-26
Completion
2018-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject TQ-B3203 Unknown 2 mg/m2 —
Subject TQ-B3203 Unknown 4 mg/m2 —
Subject TQ-B3203 Unknown 6 mg/m2 —
Subject TQ-B3203 Unknown 10 mg/m2 —
Subject TQ-B3203 Unknown 14 mg/m2 —
Subject TQ-B3203 Unknown 18 mg/m2 —

Indications

cancer